(Q38111887)

29 August 2017

Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries (English)

1 reference

29 August 2017

1 reference

cryptococcal meningitis

1 reference

4

Nathan Ford

1 reference

29 August 2017

Nelesh Govender

7

1 reference

ORCID Public Data File 2021

author name string

Angela Loyse

1

1 reference

29 August 2017

Harry Thangaraj

2

1 reference

29 August 2017

Philippa Easterbrook

3

1 reference

29 August 2017

Monika Roy

5

1 reference

29 August 2017

Tom Chiller

6

1 reference

29 August 2017

Thomas S Harrison

8

1 reference

29 August 2017

Tihana Bicanic

9

1 reference

29 August 2017

2 June 2013

1 reference

Lancet Infectious Diseases

29 August 2017

1 reference

29 August 2017

13

1 reference

29 August 2017

629-637

1 reference

29 August 2017

7

1 reference

Driving a decade of change: HIV/AIDS, patents and access to medicines for all.

29 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Trade, TRIPS, and pharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Amphotericin B: current understanding of mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Amphotericin B: spectrum and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Fungal Burden, Early Fungicidal Activity, and Outcome in Cryptococcal Meningitis in Antiretroviral-Naive or Antiretroviral-Experienced Patients Treated with Amphotericin B or Fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Combination antifungal therapy for cryptococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Liposomal amphotericin B (Fungisome) for the treatment of cryptococcal meningitis in HIV/AIDS patients in India: a multicentric, randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

The global access initiative at the University of British Columbia (UBC): Availability of UBC discoveries and technologies to the developing world

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

1 reference

7 January 2021

Pharmacological Studies with 5-Fluorocytosine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Treatment of cryptococcal meningitis in mice with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Azole antifungal agents: emphasis on new triazoles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts--time to implement in South Africa?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Access to fluconazole in less-developed countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Free fluconazole for cryptococcal meningitis: too little of a good thing?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

A comparison of cases of paediatric-onset and adult-onset cryptococcosis detected through population-based surveillance, 2005-2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Social leverage of intellectual property: road to the development of better therapy for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

Molecular farming, patents and access to medicines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970078-1

7 January 2021

10.1016/S1473-3099(13)70078-1

Identifiers

DOI

1 reference

29 August 2017

1 reference